Salute e Benessere

Boehringer Ingelheim and Re-Vana Therapeutics Announce Strategic Collaboration…

· Up to three development programs per year leading to a potential total deal value exceeding $1 billion contingent on milestone achievements.Ingelheim, Germany, Tampa, Florida, USA, and Belfast, Northern Ireland, UK [28 July 2025] –Boehringer Ingelheim and Re-Vana Therapeutics, a US and UK based developer of ocular therapeutics and ocular drug delivery technologies, today announced a strategic collaboration and license agreement that aims to develop first-in-class...
Nasdaq GlobeNewswire
28/07/2025

Cannabis Market worth $125.76 billion by 2030- Exclusive Report by…

Browse in-depth TOC on "Cannabis Market" Browse in-depth TOC on "Cannabis Market" 150– Tables 50– Figures 250– Pages Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=201768301 By application, nutraceutical & wellness form the fastest-growing segment in the global cannabis market. Nutraceutical and wellness-use cannabis includes cannabis-based products designed to support health, nutrition, and overall wellness without producing...
PR Newswire
28/07/2025

Dental Market to Grow at a CAGR of 6.3% from 2025 to 2032 | SkyQuest Technology…

Download Sample Pages of Research Overview: Download Sample Pages of Research Overview: https://www.skyquestt.com/sample-request/dental-market Dental Market Dynamics: The dental market has experienced significant growth owing to rising aesthetic consciousness, social media influence, and increasing disposable incomes have boosted demand for cosmetic dental procedures such as teeth whitening, veneers, and aligners. Patients prioritize appearance and smile makeovers, prompting...
PR Newswire
28/07/2025

Embolx Launches Sniper G3: Revolutionizing Embolization with Enhanced…

"Sniper G3 truly exemplifies our dedication to innovation driven by physician needs," said Michael Allen, President and CEO of Embolx. "We listened intently to our users and engineered a device that not only extends product longevity and improves performance, but also significantly enhances the ease of use, which translates directly to more efficient procedures. We are incredibly proud of Sniper G3 and its potential to set a new standard in embolization therapy." "…
PR Newswire
28/07/2025

Zymeworks Announces FDA Clearance of Investigational New Drug Application for…

Second antibody-drug conjugate (ADC) to progress into clinical development utilizing our proprietary payload and optimized antibodyPreclinical results demonstrate strong anti-tumor activity and favorable tolerability profilePhase 1 clinical trial evaluating ZW251 in hepatocellular carcinoma (HCC) expected to be initiated in 2025 VANCOUVER, British Columbia, July28, 2025(GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a...
Nasdaq GlobeNewswire
28/07/2025

Consortium Led by Nordic Capital and Permira Will Make All-Cash Recommended…

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTIONCOPENHAGEN, Denmark, July 28, 2025– Bavarian Nordic A/S (OMX: BAVA) (“Bavarian Nordic”) announced today that it has entered into an announcement agreement with Innosera ApS (the “Offeror”), a newly formed company controlled by Nordic Capital Fund XI 1and funds managed and advised by Permira...
Nasdaq GlobeNewswire
28/07/2025

Roche presents new insights in Alzheimer’s disease research across its…

Trontinemab’s Phase Ib/IIa Brainshuttle™ AD study continues to show rapid and robust clearance of amyloid plaques, with 91% becoming amyloid PET negative and ARIA-E remaining <5%Design of the Phase III TRONTIER 1 and 2 studies of trontinemab in early symptomatic Alzheimer’s disease featured, with initiation planned in 2025Plans for new Phase III trial investigating trontinemab in preclinical Alzheimer’s disease, in people at high risk of cognitive declineNew real-world data...
Nasdaq GlobeNewswire
28/07/2025

OXURION : Information on the Total Number of Voting Rights (Denominator)…

Atlas Special Opportunities, LLC has converted 10 convertible bonds in Oxurion resulting in a EUR 250,000 capital increase. This is part of Atlas Special Opportunities, LLC's EUR 20 million Capital Commitment[1] that will allow Oxurion to focus on developing innovative therapeutics to preserve the vision of elderly people, targeting potential…
Actusnews Wire
25/07/2025

Shanton Receives Fast Track Designation from US FDA for Refractory Gout Program

"We are excited about the Fast Track designation for SAP-001" says Dr. Wenfeng Miao, Shanton's CMO. "Refractory gout is a serious condition for which there are considerable unmet medical needs, requiring the development of new treatments. We are pleased to tap into the opportunity for faster regulatory reviews provided by this designation to speed up the availability of a much-needed solution for gout patients who do not respond to or cannot tolerate Standard-of-Care treatment…
PR Newswire
25/07/2025

Healthcare Analytical Testing Services Market worth $12.48 billion by 2030 with…

Additionally, emerging markets are expected to offer lucrative growth opportunities for market players during the forecast period. Additionally, emerging markets are expected to offer lucrative growth opportunities for market players during the forecast period. Download PDF Brochure:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=108923833 Browse in-depth TOC on "Healthcare Analytical Testing Services Market" 421 - Tables 66 - Figures 408 - Pages By type, ...
PR Newswire
25/07/2025

Evaxion to present two-year clinical efficacy data from phase 2 trial with…

/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, will be presenting two-year clinical efficacy data from its phase 2 trial with lead compound EVX-01 at the European Society for Medical Oncology (ESMO) Congress 2025 to be held in Berlin, Germany, from October 17-21, 2025.Designed with Evaxion’s AI-Immunology™ platform, EVX-01 is a personalized cancer vaccine currently being evaluated as a treatment for advanced...
Nasdaq GlobeNewswire
25/07/2025

TRYNGOLZA® (olezarsen) recommended for EU approval by CHMP for familial…

"Building on the strong early launch of TRYNGOLZA in the U.S., the positive CHMP opinion advances our commitment to expand access to TRYNGOLZA globally," said Brett P. Monia, Ph.D., chief executive officer of Ionis. "TRYNGOLZA has demonstrated significant reductions in triglycerides and substantial reductions in acute pancreatitis events with favourable safety and tolerability. With this robust clinical profile, combined with Sobi's deep commercial market expertise in FCS…
PR Newswire
25/07/2025

ZURZUVAE® (zuranolone) Receives Positive Opinion from CHMP for the Treatment of…

BiogenInc. (Nasdaq: BIIB) announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending marketing authorization for ZURZUVAE ®(zuranolone) for the treatment of postpartum depression (PPD) in adults following childbirth. If approved by the European Commission (EC), ZURZUVAE will be the first treatment authorized within the European Union specifically indicated to treat depressive symptoms for women with...
Nasdaq GlobeNewswire
25/07/2025

Roche provides regulatory update on Elevidys™ gene therapy for Duchenne muscular…

EMA’s CHMP issued an opinion not to recommend Elevidys™ (delandistrogene moxeparvovec) for the treatment of ambulatory individuals with Duchenne muscular dystrophy (DMD) Roche will continue its dialogue with the EMA to explore a potential path forward to make Elevidys available to individuals living with DMD in the EURoche believes the benefit-risk remains positive in the ambulatory Duchenne populationElevidys is the first and only disease-modifying gene therapy for DMD...
Nasdaq GlobeNewswire
25/07/2025

European regulatory authority adopts positive opinion for Novo Nordisk’s Alhemo®…

Pending European Commission (EC) approval, Alhemo ®will become available to all adult and paediatric patients 12 years and older living with severe haemophilia A and moderate or severe haemophilia B without inhibitors.This positive opinion by the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) is based on results from the explorer8 trial, which showed that Alhemo ®reduced spontaneous and traumatic bleeds for patients living with haemophilia A and B...
Nasdaq GlobeNewswire
25/07/2025

Wellcome Photography Prize 2025: Winning Images Reveal Powerful Stories of…

Sujata Setia, Mithail Afrige Chowdhury and Steve Gschmeissner awarded £10,000 each for images exploring domestic abuse, climate migration and the hidden dangers of cholesterol A Thousand Cuts, Sujata Setia, 2023, Urban Travel, Mithail Afrige Chowdhury, 2023, Cholesterol in the Liver, 2022, Steve GschmeissnerClick Here to download press images and captionsLONDON, July25, 2025(GLOBE NEWSWIRE) -- Wellcome’s 2025 Photography Prize celebrates three image makers whose work reveals...
Nasdaq GlobeNewswire
25/07/2025

PHNIX Launches Global Brand Upgrade and Two Flagship Products at Guangzhou…

During the summit, Mr. Hengyi Zhao, Vice Supervisor of the China Energy Conservation Association (CECA), awarded PHNIX the title of "International Heat Pump Brand," recognizing its leadership in sustainable innovation. A distribution partner from Germany also shared insights into PHNIX's exceptional product performance and strong reputation in Europe. During the summit, Mr. Hengyi Zhao, Vice Supervisor of the China Energy Conservation Association (CECA), awarded PHNIX the title of...
PR Newswire
25/07/2025

Phase II Stage Of Pivotal Clinical Trial Of KX-826 Tincture 1.0% For The…

View original content:https://www.prnewswire.co.uk/news-releases/phase-ii-stage-of-pivotal-clinical-trial-of-kx-826-tincture-1-0-for-the-treatment-of-male-adult-aga-in-china-reached-primary-endpoint-302513822.html View original content: https://www.prnewswire.co.uk/news-releases/phase-ii-stage-of-pivotal-clinical-trial-of-kx-826-tincture-1-0-for-the-treatment-of-male-adult-aga-in-china-reached-primary-endpoint-302513822.html
PR Newswire
25/07/2025

Pfizer and BioNTech Receive Positive CHMP Opinion for LP.8.1-Adapted COVID-19…

Data indicate that the LP.8.1-adapted COVID-19 vaccine confers improved immune response against currently dominant and emerging sublineages – including the XFG and NB.1.8.1 variants1 – compared to 2024-2025 COVID-19 vaccine formulationsUpon authorization by the European Commission (EC), the LP.8.1-adapted COVID-19 vaccine will be available for individuals 6 months of age and olderTo date, over a billion adults and children around the world have received the Pfizer-BioNTech...
Nasdaq GlobeNewswire
25/07/2025

MALAYSIA HEALTHCARE TRAVEL COUNCIL LAUNCHES MYMT 2026, MALAYSIA'S FIRST MEDICAL…

In 2024, Malaysia welcomed 1.6 million healthcare travellers, reflecting a 14% year-on-year increase, and generated RM2.72 billion in revenue, a remarkable 21% growth compared to 2023. MYMT 2026 is poised to elevate these achievements, aligning with MHTC's ambitious goal of achieving RM12 billion in industry revenue by 2030. In 2024,Malaysiawelcomed 1.6 million healthcare travellers, reflecting a 14% year-on-year increase, and generatedRM2.72 billionin revenue, a remarkable 21%...
PR Newswire
25/07/2025

Press Release: Sanofi’s Sarclisa approved in the EU for the treatment of…

Sanofi’s Sarclisa approved in the EU for the treatment of transplant-eligible newly diagnosed multiple myeloma Approval based on GMMG-HD7 phase 3 study demonstrating that Sarclisa with VRd induction treatment significantly improved MRD negativity benefit and prolonged PFS compared to VRd aloneWith the first global approval in TE NDMM, Sarclisa is now approved in the EU across all lines of therapy, regardless of transplant eligibilityParis, July 25, 2025.Following thepositive...
Nasdaq GlobeNewswire
25/07/2025

Memo Therapeutics AG Announces Phase II Trial Results for Potravitug in Kidney…

Results show biopsy-proven resolution of BK polyomavirus nephropathy in kidney transplant recipients No safety or tolerability concerns were observedSupports progression into Phase III development with the potential to transform the treatment landscape for kidney transplant patients with BK polyomavirus infectionFurther results from the trial to be presented at the World Transplant Congress in San Francisco, 2-6 August Schlieren / Zurich, Switzerland, 25 July, 2025 – Memo...
Nasdaq GlobeNewswire
25/07/2025

CD40/CD40L Inhibitors Market on Growth Trajectory Driven by Advancements in…

Key Takeaways from the CD40/CD40L Inhibitors Market Report Key Takeaways from the CD40/CD40L Inhibitors Market Report Discover which indication is expected to grab the major CD40/CD40L inhibitors market share @CD40/CD40L Inhibitors Market Report CD40/CD40L Inhibitors Market Dynamics The CD40/CD40L signaling pathway plays a pivotal role in modulatingimmune responses, inflammation, and tumor immunity. Overactivation of this pathway has been implicated in a variety of...
PR Newswire
24/07/2025

B7-H4 Targeting Therapies Market Growth Set to Accelerate Across the 7MM During…

Key Takeaways from the B7-H4 Targeting Therapies Market Report Key Takeaways from the B7-H4 Targeting Therapies Market Report Discover which indication is expected to grab the major B7-H4 targeting therapies market share @B7-H4 Targeting Therapies Market Report B7-H4 Targeting Therapies Market Dynamics The B7-H4 targeting therapies market is rapidly emerging as a promising frontier in immuno-oncology. B7-H4 is a member of the B7 family of immune checkpoint molecules that has...
PR Newswire
24/07/2025
Altri  Comunicati